{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:07:11Z","timestamp":1787162831037,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extensive macular atrophy with pseudodrusen-like appearance (EMAP) is a rare retinal disorder characterized by bilateral macular atrophy and subretinal drusenoid deposits (SDDs), typically occurring earlier and progressing faster than age-related macular degeneration. A possible association between EMAP and rheumatic fever (RF) has been proposed, but its prevalence in this population remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study, 118 patients (236 eyes) with valvular disease secondary to RF were prospectively screened at a tertiary cardiology clinic. EMAP was defined by vertically predominant macular atrophy with SDDs and exclusion of alternative diagnoses. Multimodal imaging included spectral-domain optical coherence tomography and fundus autofluorescence. Demographic, clinical, and cardiologic parameters were descriptively analyzed between patients with and without EMAP, and compared between those with and without SDDs using appropriate statistical tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two patients (1.69%; 95% confidence interval [CI], 0.47\u20135.97%) met diagnostic criteria for EMAP. Both were women aged 62 and 73 years, with RF onset during childhood and long disease duration (54 and 62 years). SDDs were identified in 12 patients (10.17%; 95% CI, 5.91\u201316.94%), including both EMAP cases. Patients with SDDs were significantly older (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007), had longer RF duration (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032), and received a greater cumulative benzathine penicillin prophylaxis burden (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EMAP is uncommon among patients with RF-associated valvular disease, suggesting that additional genetic or environmental factors may be necessary for disease manifestation. The prevalence of SDDs highlights potential subclinical retinal involvement associated with chronic systemic inflammation in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00805-6","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:57:28Z","timestamp":1770047848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing the prevalence of extensive macular atrophy with pseudodrusen-like appearance in patients with rheumatic fever-associated valvular heart disease: a cross-sectional study"],"prefix":"10.1186","volume":"12","author":[{"given":"Antonio S. F.","family":"Cassavia Junior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Bellanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia O.","family":"Audi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Castilho S.","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata A. M.","family":"Caravelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo J.","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique T.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"805_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ajo.2008.10.022","volume":"147","author":"CP Hamel","year":"2009","unstructured":"Hamel CP, Meunier I, Arndt C, et al. Extensive macular atrophy with pseudodrusen-like appearance: a new clinical entity. Am J Ophthalmol. 2009;147:609\u201320. https:\/\/doi.org\/10.1016\/j.ajo.2008.10.022.","journal-title":"Am J Ophthalmol"},{"key":"805_CR2","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s00417-024-06600-z","volume":"262","author":"MM Carl\u00e0","year":"2024","unstructured":"Carl\u00e0 MM, Giannuzzi F, Boselli F, et al. Extensive macular atrophy with pseudodrusen-like appearance: comprehensive review of the literature. Graefes Arch Clin Exp Ophthalmol. 2024;262:3085\u201397. https:\/\/doi.org\/10.1007\/s00417-024-06600-z.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"805_CR3","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.ophtha.2016.05.018","volume":"123","author":"A Douillard","year":"2016","unstructured":"Douillard A, Picot M-C, Delcourt C, et al. Clinical characteristics and risk factors of extensive macular atrophy with pseudodrusen: the EMAP Case-Control National clinical trial. Ophthalmology. 2016;123:1865\u201373. https:\/\/doi.org\/10.1016\/j.ophtha.2016.05.018.","journal-title":"Ophthalmology"},{"key":"805_CR4","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.ophtha.2024.04.001","volume":"131","author":"A Antropoli","year":"2024","unstructured":"Antropoli A, Bianco L, Condroyer C, et al. Extensive macular atrophy with Pseudodrusen-like appearance: progression kinetics and Late-Stage findings. Ophthalmology. 2024;131:1175\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2024.04.001.","journal-title":"Ophthalmology"},{"key":"805_CR5","doi-asserted-by":"publisher","unstructured":"Querques G, Blanco R, Puche N et al. Extensive macular atrophy with pseudodrusen-like appearance. Ophthalmology. 2013;120:429.e1-2. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.027.","DOI":"10.1016\/j.ophtha.2012.09.027"},{"key":"805_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10633-023-09941-y","volume":"147","author":"SES Watanabe","year":"2023","unstructured":"Watanabe SES, Quercia AZF, Sacai PY. Electrophysiological findings in extensive macular atrophy with Pseudodrusen. Doc Ophthalmol Adv Ophthalmol. 2023;147:121\u201330. https:\/\/doi.org\/10.1007\/s10633-023-09941-y.","journal-title":"Doc Ophthalmol Adv Ophthalmol"},{"key":"805_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40942-024-00592-y","volume":"10","author":"CA Moreira-Neto","year":"2024","unstructured":"Moreira-Neto CA, Schmidt Andujar RA, Chao JCT, et al. Rheumatic fever and long-term use of benzathine penicillin as possible risk factors for extensive macular atrophy with Pseudodrusen in a Brazilian cohort. Int J Retina Vitr. 2024;10:75. https:\/\/doi.org\/10.1186\/s40942-024-00592-y.","journal-title":"Int J Retina Vitr"},{"key":"805_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s10792-025-03713-0","volume":"45","author":"SES Watanabe","year":"2025","unstructured":"Watanabe SES, Quercia AZF, de Assis GPSM, et al. Ganglion cell function loss in extensive macular atrophy with Pseudodrusen. Int Ophthalmol. 2025;45:338. https:\/\/doi.org\/10.1007\/s10792-025-03713-0.","journal-title":"Int Ophthalmol"},{"key":"805_CR9","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.ophtha.2015.03.027","volume":"122","author":"M Lindner","year":"2015","unstructured":"Lindner M, B\u00f6ker A, Mauschitz MM, et al. Directional kinetics of geographic atrophy progression in Age-Related macular degeneration with foveal sparing. Ophthalmology. 2015;122:1356\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.027.","journal-title":"Ophthalmology"},{"key":"805_CR10","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.ophtha.2013.03.029","volume":"120","author":"N Joachim","year":"2013","unstructured":"Joachim N, Mitchell P, Kifley A, et al. Incidence and progression of geographic atrophy: observations from a population-based cohort. Ophthalmology. 2013;120:2042\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.029.","journal-title":"Ophthalmology"},{"key":"805_CR11","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1167\/iovs.08-2484","volume":"50","author":"S Schmitz-Valckenberg","year":"2009","unstructured":"Schmitz-Valckenberg S, Fleckenstein M, Helb H-M, et al. In vivo imaging of foveal sparing in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50:3915\u201321. https:\/\/doi.org\/10.1167\/iovs.08-2484.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"805_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ophtha.2015.09.036","volume":"123","author":"S Schmitz-Valckenberg","year":"2016","unstructured":"Schmitz-Valckenberg S, Sahel J-A, Danis R, et al. Natural history of geographic atrophy progression secondary to Age-Related macular degeneration (Geographic atrophy progression Study). Ophthalmology. 2016;123:361\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.036.","journal-title":"Ophthalmology"},{"key":"805_CR13","doi-asserted-by":"publisher","first-page":"101320","DOI":"10.1016\/j.preteyeres.2024.101320","volume":"104","author":"A Antropoli","year":"2025","unstructured":"Antropoli A, Bianco L, Romano F, et al. Extensive macular atrophy with pseudodrusen-like appearance (EMAP) clinical characteristics, diagnostic criteria, and insights from allied inherited retinal diseases and age-related macular degeneration. Prog Retin Eye Res. 2025;104:101320. https:\/\/doi.org\/10.1016\/j.preteyeres.2024.101320.","journal-title":"Prog Retin Eye Res"},{"key":"805_CR14","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1016\/j.xops.2021.100016","volume":"1","author":"F Romano","year":"2021","unstructured":"Romano F, Airaldi M, Cozzi M, et al. Progression of atrophy and visual outcomes in extensive macular atrophy with Pseudodrusen-like appearance. Ophthalmol Sci. 2021;1:100016. https:\/\/doi.org\/10.1016\/j.xops.2021.100016.","journal-title":"Ophthalmol Sci"},{"key":"805_CR15","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.3390\/jcm10102072","volume":"10","author":"P Lin","year":"2021","unstructured":"Lin P, McClintic SM, Nadeem U, et al. A review of the role of the intestinal microbiota in Age-Related macular degeneration. J Clin Med. 2021;10:2072. https:\/\/doi.org\/10.3390\/jcm10102072.","journal-title":"J Clin Med"},{"key":"805_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3109\/08916939508995305","volume":"22","author":"MP Lerner","year":"1995","unstructured":"Lerner MP, Donoso LA, Nordquist RE, et al. Immunological mimicry between retinal S-antigen and group A Streptococcal M proteins. Autoimmunity. 1995;22:95\u2013106. https:\/\/doi.org\/10.3109\/08916939508995305.","journal-title":"Autoimmunity"},{"key":"805_CR17","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1136\/hrt.2007.141309","volume":"94","author":"KB Tibazarwa","year":"2008","unstructured":"Tibazarwa KB, Volmink JA, Mayosi BM. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart Br Card Soc. 2008;94:1534\u201340. https:\/\/doi.org\/10.1136\/hrt.2007.141309.","journal-title":"Heart Br Card Soc"},{"key":"805_CR18","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.ophtha.2015.12.034","volume":"123","author":"AV Zarubina","year":"2016","unstructured":"Zarubina AV, Neely DC, Clark ME, et al. Prevalence of subretinal drusenoid deposits in older persons with and without Age-Related macular Degeneration, by multimodal imaging. Ophthalmology. 2016;123:1090\u2013100. https:\/\/doi.org\/10.1016\/j.ophtha.2015.12.034.","journal-title":"Ophthalmology"},{"key":"805_CR19","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1167\/iovs.19-27283","volume":"60","author":"P-H Gabrielle","year":"2019","unstructured":"Gabrielle P-H, Seydou A, Arnould L, et al. Subretinal drusenoid deposits in the elderly in a Population-Based study (the Montrachet study). Invest Ophthalmol Vis Sci. 2019;60:4838\u201348. https:\/\/doi.org\/10.1167\/iovs.19-27283.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"805_CR20","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1167\/iovs.15-18816","volume":"57","author":"GHS Buitendijk","year":"2016","unstructured":"Buitendijk GHS, Hooghart AJ, Brussee C, et al. Epidemiology of reticular Pseudodrusen in Age-Related macular degeneration: the Rotterdam study. Invest Ophthalmol Vis Sci. 2016;57:5593\u2013601. https:\/\/doi.org\/10.1167\/iovs.15-18816.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"805_CR21","doi-asserted-by":"publisher","first-page":"25569","DOI":"10.1038\/s41598-024-76342-9","volume":"14","author":"N Lishinsky-Fischer","year":"2024","unstructured":"Lishinsky-Fischer N, Misgav K, Chowers I, et al. Association of subretinal drusenoid deposits and cardiovascular disease. Sci Rep. 2024;14:25569. https:\/\/doi.org\/10.1038\/s41598-024-76342-9.","journal-title":"Sci Rep"},{"key":"805_CR22","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.3390\/jcm11206012","volume":"11","author":"M Kukan","year":"2022","unstructured":"Kukan M, Driban M, Vupparaboina KK, et al. Structural features of patients with Drusen-like deposits and systemic lupus erythematosus. J Clin Med. 2022;11:6012. https:\/\/doi.org\/10.3390\/jcm11206012.","journal-title":"J Clin Med"},{"key":"805_CR23","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.oret.2023.06.020","volume":"7","author":"M Battaglia Parodi","year":"2023","unstructured":"Battaglia Parodi M, Antropoli A, Bianco L, et al. Peripheral retinal involvement in extensive macular atrophy with Pseudodrusen-Like deposits. Ophthalmol Retina. 2023;7:910\u20137. https:\/\/doi.org\/10.1016\/j.oret.2023.06.020.","journal-title":"Ophthalmol Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00805-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00805-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00805-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:50:34Z","timestamp":1781632234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00805-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00805-6","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the tenets of the Declaration of Helsinki and was approved by the HCRP Institutional Review Board. Written informed consent was obtained from all participants prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for participation and for the publication of anonymized clinical data and images was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}